Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR The long-term survival rate of patients who underwent allogeneic SCT (allo-SCT) with a non-CR status was as poor as 10-30% [1] [2] [3] ; however, a more appropriate indicator of the leukemic burden is needed to assess the prognosis of patients who underwent allo-SCT in non-CR. Here, we focused on patients with acute myeloid leukemia (AML) who underwent their first allo-SCT with a non-CR status, i.e., primary induction failure (PIF), first relapse (relapse 1), and second relapse (relapse 2), and investigated how the percentage of BM and PB blasts before allo-SCT influenced the transplantation outcomes. To this end, we retrospectively analyzed the data of patients with AML who underwent allo-SCT and were registered in the Transplant Registry Unified Management Program (TRUMP) system, the transplant registry of the Japan Society of Hematopoietic Stem Cell transplantation [4, 5] .
The TRUMP database includes data from 8224 patients with AML who underwent their first allo-SCT (rBMT, rPBSCT, uBMT, or uCBT) between 2001 and 2011. Among them, 3098 patients underwent any allo-SCT in non-CR (relapse 1, relapse 2, or PIF status). In Japan, the majority of patients newly diagnosed with AML receive chemotherapy according to the Japan Leukemia Study Group AML protocol [6, 7] , and patients who do not achieve a CR after at least two cycles of induction Hiroyasu Ogawa and Kazuhiro Ikegame contributed equally to this work.
chemotherapy are usually treated as PIF. Both BM and PB blast% before the start of conditioning were reported in 929 (37.3%) of 3098 patients undergoing all-SCT in non-CR. The characteristics of 929 patients of whom data were analyzed are shown in Supplemental Table 1 .
The relationship between BM and PB blast% is shown in Supplemental Fig. 1 . The two factors showed a weak positive correlation (ρ = 0.622). We first intended to confirm which of BM or PB blast% had a stronger impact on the survival of patients who underwent allo-SCT in non-CR. To this end, factors that were associated with overall survival (OS), including the continuous data of BM and PB blast%, patient age (15-40, 41-50, and 51-70), HCT-CI, time interval from diagnosis to transplantation (<12 vs. ≥12 months), donor-recipient sex combination (female donor to male recipient vs. all other), intensity of conditioning (MAC vs. RIC), chromosomal karyotype (good/ intermediate vs. poor), stem cell source (rBMT, rPBSCT, uBMT, and uCBT), disease status (relapse 1, relapse 2, and PIF), and year at transplantation, were analyzed using the Cox proportional hazards model. As shown in Supplemental Table 2 , BM blast% was significantly correlated with poor survival (hazard ratio (HR) = 1.009, p < 0.0001), but not PB blast%, indicating that BM blast% was more important than PB blast% for the prediction of OS.
Next, we categorized patients into one of three BM blast % groups: BM blasts ≤20% (low), 20% < BM blasts ≤ 60% (intermediate), and 60% < BM blasts (high), as described in Supplemental Materials and Methods. In addition, the presence or absence of PB blasts was selected as a variable for multivariable analysis, as the presence of PB blasts was reported to have a negative impact on survival [1] . Consequently, both categorized BM blast% and the presence of PB blasts were found to be factors significantly correlated with poor survival (Supplemental Table 3 ).
To further clarify the importance of BM and PB blasts on survival, we categorized patients in non-CR into one of six groups, i.e., we categorized BM blast% with or without the presence of PB blasts, and performed a multivariable analysis of OS. Based on the HR of the six groups on survival (Supplemental Table 4 ), we could categorize patients into one of three new groups, i.e., low BM blast% with absence of PB blasts (leukemic burden A), low BM blast% with presence of PB blasts, or intermediate BM blast% with or without presence of PB blasts (leukemic burden B), and high BM blast% with or without presence of PB blasts (leukemic burden C). Using the leukemic burden combining BM and PB blasts, we again performed multivariable analysis of OS (Table 1) . Consequently, an increase in the leukemic burden was correlated with a stepwise increase in the HR of death. The adjusted survival of the three leukemic burden groups is shown in Fig. 1a . The adjusted 2-year survival rates were 43.9, 29.1, and 20.3% for leukemic burdens A, B, and C, respectively.
Regarding other factors associated with OS, a poor karyotype, RIC, time interval from diagnosis to transplantation <1 year, and increased age had a significant negative impact on OS (Table 1) . On the other hand, there was no significant difference in OS regarding donor-recipient sex matching combination, stem cell source, HCT-CI, disease status, or years at allo-SCT.
Thirty-six (13.6%), 130 (26.9%), and 71 (39.2%) patients with leukemic burden levels A, B, and C had not achieved CR after allo-SCT, respectively. For relapse, an increase in the leukemic burden was correlated with an increase in the HR of relapse (Table 1, Fig. 1b) . Furthermore, in the analysis of patients who achieved CR after allo-SCT, leukemic burden levels B (HR = 1.426, p = 0.0380) and C (HR = 1.975, p = 0.0031) demonstrated a significantly higher relapse rate compared with leukemic burden level A. For NRM, there was no significant difference among the leukemic burden levels (Fig. 1c, Table 1 ).
We next analyzed whether leukemic burden levels influenced hematopoietic recovery after transplantation. Neutrophil engraftment (absolute neutrophil count >0.5 × 10 9 /L) was achieved at a median of 18, 19, and 22 days after transplantation for leukemic burden levels A, B, and C, respectively (Supplemental Figure 2A) . The unsupported platelet count of 20 × 10 9 /L was achieved at a median of 31, 41, and 52 days after transplantation for leukemic burden levels A, B, and C, respectively (Supplemental Figure 2B) . On multivariable analyses, both neutrophil and platelet recoveries were significantly higher in leukemic burden level A than in leukemic burden level C. In addition, platelet recovery tended to be higher in level A than in level B (p = 0.064), although the difference was not significant.
The aim of this study was to investigate a more appropriate indicator of the leukemic burden to assess the prognosis of patients who underwent allo-SCT in non-CR. Consequently, we could reasonably categorize patients into one of three leukemic burden levels: level A (low BM blast% and the absence of PB blasts), level B (low BM blast% and the presence of PB blasts, or intermediate BM blast%), or level C (high BM blast%) based on HR. These data suggest that the presence or absence of PB blasts was meaningful as a prognostic factor only for the low BM blast% level (≤20%), and not for the intermediate or high BM blast% level. We found that an increase in the leukemic burden was correlated with a stepwise decrease in OS (Table 1, Fig. 1a) . In this regard, it is important for patients undergoing allo-SCT in non-CR to be categorized into one of three groups by levels of leukemic burden based on the risk of death. As expected, a higher leukemic burden was associated with an increase in relapse, which reduces the OS (Table 1, Fig. 1) . A high leukemic burden before transplantation is considered to lead to a decrease in the effector/tumor The risk classification of karyotypes was performed according to the recent criteria [10] e MAC and RIC were defined according to the criteria reported as the workshop convened by the Center for International Blood and Marrow Transplant Research [11] f A median time interval from diagnosis to transplantation <12 and ≥12 months was 261 days (range 25-365 days) and 512 days (range 366-3963 days), respectively g The median CR1 duration of patients undergoing allo-SCT at relapse 1 was 190.5 days. The percentage of patients who had a CR1 duration <6 months was 45.8%. The median CR1 and CR2 duration of patients undergoing allo-SCT at relapse 2 was 301 and 111.5 days, respectively ratio on day 0, which results in an increase in the relapse rate. Of interest, an increase in the leukemic burden level increased the failure rate of CR induction after allo-SCT (13.6, 26.9, and 39.2% of patients with leukemic burden levels A, B, and C had not achieved CR after allo-SCT, respectively). In the multivariable analysis of data of 509 patients with PIF, an increase in the leukemic burden was also correlated with a stepwise decrease in OS (data not shown). Although one limitation is the fact is that the presence of extramedullary diseases in the low leukemic burden group may add a bias to the results, we could not analyze this possibility.
In the present study, RIC was a negative factor for survival. On multivariable analysis, RIC was significantly correlated with delaying neutrophil recovery (p = 0.0342) and increasing the incidence of NRM (p = 0.027), suggesting that the delay of neutrophil recovery increased NRM. Regarding the fact that a female donor for a male recipient was not associated with poor survival, this donor/recipient sex combination may have become negligible for patients with very advanced disease because it significantly reduced the relapse rate [8] . Furthermore, a longer interval from diagnosis to transplant (≥12 months) was not a poor risk factor, but rather a good risk factor for survival because of the lower relapse rate in these non-CR patients. In this regard, there is a difference among diseases, and in AML, the relative risk of >12 months has been reported to be lower than that of ≤12 months [9] .
In conclusion, we demonstrated that using the leukemic burden levels, combining BM blast% levels and the presence or absence of PB blasts, patients in non-CR could be categorized into one of three leukemic burden groups, and that the leukemic burden levels had a significant impact on relapse, OS, and the hematopoietic reconstitution. These findings will provide transplant experts with important information, especially when they encounter transplant patients with AML in non-CR.
